Loading...
01/10 16:57
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call summary shows strong financial performance, innovative product development, and strategic market positioning, with positive guidance on sales and income growth. The Q&A section supports optimism with management's confidence in product growth and strategic initiatives. Shareholder returns are strong with ongoing buybacks. Despite some uncertainties in pricing policies, the overall sentiment is positive, suggesting a likely stock price increase.
Sales Growth Sales were up 11% in constant currency year-over-year. This growth was driven by strong performance across priority brands and innovation highlights.
Core Operating Income Core operating income increased by 21% in constant currency year-over-year. This was supported by productivity programs and strong sales growth.
Core Margin Core margin improved by 340 basis points to 42.2% year-over-year. This reflects operational efficiencies and strong revenue growth.
Core EPS Core EPS increased by 24% to $2.42 year-over-year, reflecting strong operating income growth.
Free Cash Flow Free cash flow increased by 37% to $6.3 billion year-over-year, driven by strong operating income and cash conversion.
Kisqali Sales Kisqali sales grew 64% year-over-year, driven by strong growth in metastatic breast cancer and early breast cancer launches, particularly in the U.S. and Europe.
Kesimpta Sales Kesimpta sales grew 33% year-over-year, fueled by strong demand for self-administered B-cell therapy for MS, with significant growth in the U.S. and Europe.
Pluvicto Sales Pluvicto sales increased by 30% year-over-year, driven by the pre-taxane indication approval in the U.S. and strong uptake in community settings.
Leqvio Sales Leqvio sales grew 61% year-over-year, with strong performance in the U.S. and China, driven by expanded use in lipid-lowering treatments.
Scemblix Sales Scemblix sales grew 79% year-over-year, driven by strong momentum in early lines of therapy and global leadership in the third-line setting.
Cosentyx Sales Cosentyx sales grew 6% year-over-year, with solid demand in the U.S. for new indications but moderated growth due to geographic-specific headwinds and pricing impacts.
Entresto Sales Entresto sales showed consistent growth, with half of the sales coming from Europe, China, and Japan. U.S. sales were $1.2 billion in Q2.
Free Cash Flow (First Half) Free cash flow for the first half of 2025 increased by 46% year-over-year, reflecting strong operating income and cash conversion.
OAV101 IT: Submissions in the U.S. and Europe.
Votoplam: Milestones reached in Huntington's disease.
Kisqali: 64% growth in Q2, leadership in metastatic breast cancer, and early breast cancer launch momentum.
Kesimpta: 33% growth, strong demand for self-administered B-cell therapy for MS.
Pluvicto: 30% growth, driven by pre-taxane indication approval in the U.S. Ex-U.S. growth driven by Europe with expanding reimbursement.
Leqvio: 61% growth, on track to exceed $1 billion in sales. 74% growth outside the U.S., driven by China.
Scemblix: 79% growth, strong momentum in early lines and global leadership in third-line setting. Approved in 20 countries, including China and Japan.
Cosentyx: 6% growth, facing geographic-specific headwinds but maintaining mid-single-digit growth expectations.
Entresto: Solid growth, U.S. mid-2025 LOE expected.
Fabhalta: Steady growth in the U.S., approved in over 30 countries. Approved in over 30 countries, including Japan.
Vanrafia: Strong HCP feedback and exceeding early targets for patient enrollment.
Zigakibart: 100-week data shows 60% proteinuria reduction and sustained eGFR stabilization.
Remibrutinib: Phase II study in food allergy met primary endpoint, Phase III planning underway.
YTB (CAR-T): Interim Phase I/II data shows strong results in severe refractory SLE.
Geographic Expansion: Kisqali early breast cancer indication approved in Europe, China, and 18 other countries.
Core Operating Income: Upgraded guidance, 21% growth in Q2.
Free Cash Flow: $6.3 billion in Q2, up 37%.
Share Buyback: New $10 billion program announced, targeted for completion by 2027.
Pipeline Investments: Acquisition of Regulus Therapeutics to strengthen renal pipeline.
Leadership Transition: Harry Kirsch to retire as CFO in March 2026, Mukul Mehta to succeed.
Pipeline Development: Advancing YTB in autoimmune diseases and Remibrutinib in food allergy.
Entresto U.S. Generic Entry: Potential mid-2025 generic entry for Entresto in the U.S. could significantly impact sales, with each month of sales worth $400 million. This poses a risk to revenue and growth projections.
Cosentyx Growth Challenges: Growth moderated to 6% in Q2 due to geographic-specific headwinds, including higher rebates in the U.S., Medicare Part D redesign, and new competitor entry in HS. Pricing impacts from new indications and a market-wide slowdown in China also contribute to challenges.
Pluvicto Supply Chain and Expansion: While Pluvicto showed robust growth, its success depends on maintaining a strong supply chain and expanding treatment sites. Any disruption could impact its growth trajectory.
Regulatory and IP Litigation: Ongoing litigation for Entresto and other products creates uncertainty. A negative outcome could lead to earlier-than-expected generic competition.
Economic and Market-Specific Risks: Pricing pressures in Europe and China, as well as market-wide slowdowns, could impact revenue growth for key products like Cosentyx and Leqvio.
Pipeline and R&D Risks: Delays or failures in clinical trials, such as the Phase III study for Zigakibart or other pipeline products, could hinder future growth and innovation.
Competitive Pressures: New competitor entries in key therapeutic areas, such as HS for Cosentyx, could erode market share and impact sales.
Operational Execution Risks: The success of new launches and expansions, such as Kisqali in early breast cancer and Pluvicto in new indications, depends on effective execution. Any missteps could impact growth.
Full Year 2025 Guidance: Novartis upgraded its full-year 2025 bottom-line guidance. Sales are expected to grow in high single digits, and core operating income is projected to grow in the low teens (13%-14%). This assumes a mid-2025 U.S. generic entry for Entresto.
Entresto U.S. Generic Entry: The company assumes a mid-2025 U.S. generic entry for Entresto for financial forecasting purposes. Each month of U.S. Entresto sales is valued at $400 million. Outside the U.S., Entresto is protected through November 2026 in Europe and until 2030 in Japan.
Pluvicto Expansion: Pluvicto is expected to gain FDA approval for metastatic hormone-sensitive prostate cancer in 2026. The company plans to submit data in the second half of 2025.
Leqvio Sales Growth: Leqvio is on track to exceed $1 billion in sales, with strong growth in the U.S. (47%) and outside the U.S. (74%). The company is expanding its evidence base and pursuing pediatric submissions and monotherapy frontline settings.
Scemblix Sales Growth: Scemblix is expected to exceed $1 billion in sales in 2025, with strong momentum in early lines of therapy and global leadership in the third-line setting.
Cosentyx Growth Outlook: Cosentyx is expected to maintain mid-single-digit growth over the coming years, with a peak sales guidance of $8 billion by 2029.
Renal Portfolio Development: The company is advancing its renal portfolio, including Fabhalta, Vanrafia, and Zigakibart. The BEYOND Phase III study for Zigakibart is expected to read out in the first half of 2026.
Remibrutinib Development: Phase III planning for Remibrutinib in food allergy is underway, with potential to address a $10 billion global market. The company is also advancing Remibrutinib in CSU, CIndU, multiple sclerosis, and myasthenia gravis.
YTB Immune Reset Therapy: Novartis is advancing YTB in a range of autoimmune diseases, with pivotal studies in lupus, systemic sclerosis, myositis, and AAV. Early-stage programs are also underway for refractory RA, Sjogren's disease, and MS.
Share Buyback Program: Novartis announced a new up to $10 billion share buyback program targeted for completion by the end of 2027.
Dividend Payout: Novartis paid $7.8 billion in the first half of 2025 as part of its annual dividend to shareholders. The company remains committed to a strong and growing dividend in Swiss francs.
New Share Buyback Program: Novartis announced a new share buyback program of up to $10 billion, targeted for completion by the end of 2027. This follows the completion of a previous $15 billion share buyback program earlier in the month. The buyback is part of the company's balanced capital allocation strategy and does not limit its ability to pursue value-creating bolt-on acquisitions.
The earnings call summary indicates a positive outlook with strong sales growth, strategic product expansions, and a significant share buyback program. Despite some margin pressure from generic competition, Novartis plans to offset it with productivity improvements. The Q&A reveals confidence in product launches and market strategies, with no major negative sentiments from analysts. The upgraded guidance and share buyback plan further support a positive sentiment, suggesting a likely stock price increase of 2% to 8% over the next two weeks.
The earnings call summary shows strong financial performance, innovative product development, and strategic market positioning, with positive guidance on sales and income growth. The Q&A section supports optimism with management's confidence in product growth and strategic initiatives. Shareholder returns are strong with ongoing buybacks. Despite some uncertainties in pricing policies, the overall sentiment is positive, suggesting a likely stock price increase.
The earnings call summary indicates strong financial performance, with impressive EPS growth, increased free cash flow, and upgraded guidance for sales and operating income. The company is committed to shareholder returns via dividends and share buybacks. While there are some concerns about regulatory issues and competitive pressures, management has taken steps to mitigate risks. The Q&A session revealed some uncertainty regarding tariffs and investment timelines, but overall sentiment remains positive with a focus on growth and innovation.
The earnings call presents strong financial performance with increased net sales, core operating income, and margins. The raised sales and income guidance, along with significant shareholder returns via dividends and buybacks, are positive indicators. The Q&A section reveals management's confidence in handling tariffs and competitive pressures, despite some uncertainties regarding tariffs and generic competition. Overall, the positives outweigh the negatives, suggesting a positive stock price movement over the next two weeks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
